IDEXX Laboratories Reports Q2 2026 Revenue of $1,217M and EPS of $4.27, Raises 2026 Outlook

IDEXX LABORATORIES INC /DE

Revenue grew 10% as reported and 9% organic; CAG Diagnostics recurring revenue grew 11% as reported and 10% organic.
EPS of $4.27, up 18% as reported and 15% comparable; operating margin increased 140 bps as reported and 110 bps comparable.
IDEXX inVue Dx installed base surpassed 9,000 instruments, with over 1,600 placements during Q2 2026.
Narrows 2026 revenue guidance to $4,700M-$4,745M, up $5M at midpoint; raises EPS outlook to $14.69-$14.94.
Updates 2026 organic revenue growth outlook to 8.5%-9.7% and CAG Diagnostics recurring revenue organic growth to 9.5%-10.7%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.